

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, or claims in the application.

Listing of Claims:

Claims 1-6 (CANCELED).

7(Original). A method of modifying TALL-104 cells comprising:
culturing TALL-104 cells in an effective amount of IL-15, wherein said cells grow at a rate faster than when stimulated by IL-2, and have an altered phenotypic, cytotoxic and cytokine profile.

8(Original). The method according to claim 7 wherein said modified cells have an increased level of cytotoxicity.

9(Original). The method according to claim 7, wherein said modified cells demonstrate a change in a characteristic selected from the group consisting of increased proliferation, differentiation, growth, phenotype, adhesion molecule expression, biodistribution, cytokine production profile, and tumor target spectrum.

10(Currently Amended). The method according to claim 9 wherein upon stimulation with anti-CD3 antibody, said cytokine profile is characterized by comprises increased expression of a cytokine selected from the group consisting of IL-10, increased expression of GM-CSF, increased expression of TNF- α , and increased expression of TNF- β , and decreased expression of gamma interferon.

Claim 11(CANCELED).

12(Currently Amended). The method according to claim 9 wherein said phenotype is characterized by comprises increased expression of the cytotoxic adhesion/activation marker CD56 and decreased expression of the adhesion molecule CD38.

Claims 13-21 (CANCELED).

ELECTIONS OF CLAIMS AND SPECIES

Election of Claims

In response to the requirement to elect a single invention from the seven (7) groups, Applicant elects the claims of Group III, i.e., claims 7-13, drawn to a method of modifying TALL-104 cells including culturing the cells in IL-15, without prejudice.

Applicant reserves the right to prosecute the claims of Groups I, II, and IV-VII in a divisional application filed during the pendency of the present application.

Elections of Species

(i) In view of the election of the claims of Group III and thereby the requirement to elect one (1) cytokine production profile, Applicant hereby elects the cytokine production profile of decreased expression of gamma interferon, with traverse.

(ii) In view of the election of the claims of Group III and thereby the requirement to elect one (1) phenotype, Applicant hereby elects the phenotype of increased expression of CD56, with traverse.